Selina M. Luger, M.D., FRCPC
Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
Attending Physician , Hospital of the University of Pennsylvania
Member , Abramson Cancer Center, University of Pennsylvania
Department: Medicine
Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
3400 Civic Center Boulevard
Philadelphia, PA 19104
Perelman Center for Advanced Medicine
3400 Civic Center Boulevard
Philadelphia, PA 19104
Education
A.B. (Biochemistry)
Harvard University, 1982.
M.D.CM (Medicine)
McGill University, 1987.
Permanent linkA.B. (Biochemistry)
Harvard University, 1982.
M.D.CM (Medicine)
McGill University, 1987.
Description of Research Expertise
Leukemia, myelodysplastic syndrome, myeloproliferative disordersMDS, AML, CML, ALL
Description of Clinical Expertise
hematologic malignancies, leukemia, AML, ALL, CML, myelodysplastic syndrome, MDS, myeloproliferative disorders, stem cell transplantation, bone marrow transplantSelected Publications
Ferthio R, Bruno XJ, Garfall AL, Cohen AD, Kapur S, Lai CE, Luger SM, Stadtmauer EA, Vogl DT, Waxman A, Susanibar-Adaniya SP.: Teclistamab in multiple myeloma with coexisting myelodysplastic syndrome or acute myeloid leukemia. Haematologica Nov 2026.Zugmaier G, Goekbuget N, Luger S, Litzow M, Cario G, Locatelli F.: Depletion of CD19-positive B-cells and dexamethasone premedication may result in immune suppression in patients with B-precursor acute lymphoblastic leukemia after consolidation treatment with blinatumomab. Haematologica Nov 2026.
Zhong X, Roberts KG, Wei H, Sun Z, Montefiori LE, Kumar A, Iacobucci I, Baviskar P, Gao Q, Pölönen P, Pruett-Miller SM, Schreiber RM, Chang TC, Zhang W, Lei S, Rampersaud E, Fan Y, Wu G, Mattison RJ, Zhang Y, Racevskis J, Lazarus HM, Rowe JM, Arber DA, Wieduwilt MJ, Abou Mourad Y, Shami PJ, Baer MR, Asch AS, O'Dwyer KM, Hall A, Liedtke M, Bergeron J, Wood BL, Pratz KW, Dinner SN, Frey NV, Gore SD, Bhatnagar B, Atallah EL, Uy GL, Jeyakumar D, Lin TL, Willman CL, Podoltsev NA, DeAngelo DJ, Patel S, Elliott MA, Advani AS, Tzachanis D, Vachhani P, Bhave RR, Sharon E, Little RF, Erba HP, Stone RM, Tallman MS, Yang JJ, Luger SM, Paietta E, Litzow MR, Mullighan CG.: Genomic drivers of leukemia and blinatumomab response in adult acute lymphoblastic leukemia - the ECOG-ACRIN E1910 study. Blood Oct 2026.
Tremblay D, Chen L, Sun Z, Ganzel C, Fernandez H, Foran J, Arber DA, Lazarus H, Zhang Y, Paietta E, Bennett JM, Rowe J, Litzow M, Tallman M, Atallah E, Luger S.: Bone marrow biopsy characteristics at nadir after intensive induction therapy do not predict outcomes in adult acute myeloid leukemia patients: an analysis of ECOG-ACRIN clinical trials. Haematologica Sep 2026.
Silva WF, Yin J, Liedtke M, Claxton DF, Fulton N, Giri S, Malnassy G, Mrózek K, Paietta E, Mullighan CG, Galinsky I, Bogart JA, Grecula JC, Kennedy L, Larson RA, Stone RM, Uy GL, Luger SM, Advani AS, Stock W.: Long-term follow-up of a pediatric regimen for AYA with Ph-negative ALL: 10-year survival of CALGB 10403 (alliance). Blood Adv 10: 5487-5491, Aug 2026.
Kharfan-Dabaja MA, Kumar A, Pemmaraju N, Murthy H, Al Malki M, Bashir Q, Bubis J, Lane AA, Nishihori T, de Lima M, Gangat N, Jamy O, Konopleva M, Luger S, Savani B, Sweet K, Wang E, Carpenter PA, Hamadani M.: Hematopoietic Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm: Clinical Practice Guidelines From the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther Aug 2026.
Boulter AC, Li Y, Wang X, Zheng DJ, Pratz K, Luger S, Aplenc R, Getz KD.: Primary Cardioprotection in Frontline Anthracycline Therapy for Adult Hematologic Cancers. JAMA Netw Open 9: e2630536, Aug 2026.
Montesinos P, Altman JK, Bullinger L, Cheong JW, Fathi AT, Levis MJ, Luger S, Miyamoto T, Oliva EN, Perl AE, Récher C, Veiga RR, Wang J, Zeidan AM, Liu L, Duong Y, Rohrbach JEC, Inghirami G, Alexis K, Gosberg A, Nahar A, Burns K, Daver N, Erba HP. QuANTUM-Wild: a Phase III, randomized trial of quizartinib in newly diagnosed FLT3-ITD-negative acute myeloid leukemia. Future Oncol. 2026 Jul;22(16):1913-1924. doi: 10.1080/14796694.2026.2689464. Epub 2026 Jul 11. PMID: 42434847; PMCID: PMC13390524.: QuANTUM-Wild: a Phase III, randomized trial of quizartinib in newly diagnosed FLT3-ITD-negative acute myeloid leukemia. Future Oncology 22, July 2026.
Lee J, Sun R, Kume K, Robinson ME, Cheng Z, Cosgun KN, Ma N, Hurtz C, Geng H, Luger SM, Litzow MR, Paietta E, Chen J, Vaidehi N, Müschen M.: Dynamic feedback control of oncogenic tyrosine kinase signaling in acute leukemia. Sci Signal 19: eadw5054, Feb 2026.
Anderson DR, Gangaraju R, Sedhom WG, Hamulyák EN, Wang TF, O'Dwyer K, Carney BJ, Muthiah C, Liedtke M, Badar T, Shimony S, Robinson R, Sanfilippo K, Derkach A, Dinner S, Biemond BJ, Nemirovsky D, Goldberg LA, Kapadia AD, Levavi H, Bar-Natan M, Van Hyfte G, Bansal K, Carrier M, Fulcher J, Gerrits AM, Litzow MR, Luger S, Guru Murthy GS, Luskin M, Wolach O, Shomali W, Zwicker JI, Stock W, Leader A.: Derivation and external validation of a venous thromboembolism risk prediction model in asparaginase-treated ALL. Blood Adv 10: 593-603, Feb 2026.